European Observatory on Healthcare Systems and LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.
Expert Rev Pharmacoecon Outcomes Res. 2002 Feb;2(1):43-50. doi: 10.1586/14737167.2.1.43.
Events during 2001 raised greater awareness in the global community to the problems facing less developed countries in gaining access to essential medicines because they are not affordable. The difference between the price of medicines and income in many developing countries is significant and consequently, price stands as an important barrier to access. Steps taken this year to clarify the flexibility clauses of the Trade-Related Aspects of Intellectual Property Rights Agreement - international discussions on the feasibility of applying a differential pricing mechanism and the Global Fund to Fight AIDS, Tuberculosis and Malaria - have been important advances in the process that seeks to ensure access to affordably priced medicines. This paper reviews recent developments and proposals concerning issues of drug pricing in developing countries and discusses what still needs to be done in order to improve access.
2001 年发生的一些事件使全球社会更加认识到,由于价格昂贵,发展中国家在获得基本药物方面面临着严峻的问题。在许多发展中国家,药品价格与收入之间存在巨大差距,因此,价格成为获得药物的一个重要障碍。今年,为澄清《与贸易有关的知识产权协定》的灵活性条款采取了一些步骤,国际上也在讨论实行差别定价机制的可行性,同时设立了全球防治艾滋病、结核病和疟疾基金,这些都是在努力确保以负担得起的价格获得药物方面取得的重要进展。本文审查了最近在发展中国家药品定价问题上出现的新情况和新提案,并讨论了为改善获取途径还需要做哪些工作。